Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced two abstracts selected for presentation at the MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting, taking place from October 21-23, 2026, in Toronto, Canada.